Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) CEO Thomas J. Schuetz acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, May 27th. The stock was purchased at an average price of $2.11 per share, for a total transaction of $21,100.00. Following the completion of the purchase, the chief executive officer now directly owns 6,480,825 shares in the company, valued at $13,674,540.75. This trade represents a 0.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Compass Therapeutics Price Performance
Shares of CMPX stock traded up $0.02 during trading hours on Friday, reaching $2.14. 411,152 shares of the company traded hands, compared to its average volume of 929,139. Compass Therapeutics, Inc. has a 12-month low of $0.77 and a 12-month high of $4.08. The company has a market cap of $295.93 million, a P/E ratio of -5.78 and a beta of 1.40. The firm has a 50-day moving average price of $1.89 and a 200 day moving average price of $2.13.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). Sell-side analysts predict that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.
Institutional Trading of Compass Therapeutics
A number of large investors have recently added to or reduced their stakes in the company. Rhumbline Advisers increased its stake in Compass Therapeutics by 3.1% in the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company's stock worth $187,000 after acquiring an additional 3,822 shares during the last quarter. Invesco Ltd. increased its stake in Compass Therapeutics by 11.3% in the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company's stock worth $57,000 after acquiring an additional 4,018 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Compass Therapeutics by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company's stock worth $463,000 after acquiring an additional 5,590 shares during the last quarter. ProShare Advisors LLC increased its stake in Compass Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock worth $42,000 after acquiring an additional 9,451 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Compass Therapeutics by 31.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock worth $69,000 after acquiring an additional 11,326 shares during the last quarter. Institutional investors own 68.43% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on CMPX. Piper Sandler began coverage on Compass Therapeutics in a report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 price objective for the company. Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Wedbush reiterated an "outperform" rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, April 1st. HC Wainwright reiterated a "buy" rating and issued a $24.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 21st. Finally, D. Boral Capital restated a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a report on Monday, April 28th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $13.13.
Get Our Latest Analysis on CMPX
About Compass Therapeutics
(
Get Free Report)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Featured Stories
Before you consider Compass Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.
While Compass Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
